CLINICAL_TRIALS
trial_result
· 2022-06-06
Clinical Trial Update: NF-κB Inhibition in Amyotrophic Lateral Sclerosis [Phase 2]
Summary
Phase 2 clinical trial exploring NF-κB inhibition as a potential therapy for amyotrophic lateral sclerosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Sunnybrook Health Sciences Centre | Conditions: ALS | Phase 2 | Status: UNKNOWN